Immunocore Holdings (Immunocore Holdings) Debt-to-Revenue : 1.68 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Immunocore Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.6 Mil. Immunocore Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $599.1 Mil. Immunocore Holdings's annualized Revenue for the quarter that ended in Mar. 2024 was $358.3 Mil. Immunocore Holdings's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 1.68.

Immunocore Holdings Debt-to-Revenue Historical Data

The historical data trend for Immunocore Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings Debt-to-Revenue Chart

Immunocore Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

2.31

2.12

1.75

0.47

0.34

Immunocore Holdings Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															0.31	0.35	0.34	0.20	1.68

Competitive Comparison of Immunocore Holdings's Debt-to-Revenue

For the Biotechnology subindustry, Immunocore Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunocore Holdings's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's Debt-to-Revenue falls into.

Immunocore Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Immunocore Holdings's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.757	+	104.613)	/	315.732
	=	0.34

Immunocore Holdings's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.579	+	599.149)	/	358.332
	=	1.68

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Immunocore Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunocore Holdings (Immunocore Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

6YG:Germany 6YG:Germany

Address

92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.immunocore.com

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.